-

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day...

Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv...

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences...
Back to Newsroom